Aliskiren is the first in a new class of orally active direct renin inhibitors approved for the treatment of hypertension, and blocks the renin system at its point of activation by directly inhibiting plasma renin activity.
Side effects:
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page